Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-Stage Renal Disease.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Aug 2015
At a glance
- Drugs Anti-digoxin polyclonal antibody (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 24 May 2012 Planned End Date changed from 1 Feb 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
- 24 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 May 2009 Actual initiation date (Apr 2009) added as reported by ClinicalTrials.gov.